Journal of Hepatology
Volume 52, Issue 2 , Pages 272-279 , February 2010

Liver grafts from anti-hepatitis B core positive donors: A systematic review

  • Evangelos Cholongitas

      Affiliations

    • The Royal Free Sheila Sherlock Liver Centre and University, Department of Surgery, Royal Free Hospital, Pond Street, Hampstead, London NW3 2QG, UK
    • ,
  • George V. Papatheodoridis

      Affiliations

    • 2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital, 114 Vas. Sophias Ave., 115 27 Athens, Greece
    • Corresponding Author InformationCorresponding author. Tel.: +30 210 7774742; fax: +30 210 7706871.
    • ,
  • Andrew K. Burroughs

      Affiliations

    • The Royal Free Sheila Sherlock Liver Centre and University, Department of Surgery, Royal Free Hospital, Pond Street, Hampstead, London NW3 2QG, UK

References 

  1. Nadig SN, Bratton CF, Karp SJ. Marginal donors in liver transplantation: expanding the donor pool. J Surg Educ. 2007;64:46–50
  2. Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology. 2000;31:488
  3. Mason A, Xu L, Guo L, Kuhns M, Perrillo R. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology. 1998;27:1736–1742
  4. Scullard G, Smith C, Merigan T, Robinson W, Gregory P. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology. 1981;81:987–991
  5. Rokuhara A, Tanaka E, Yagi S, Mizokami M, Hasshikura Y, Kawasaki S, et al. De novo infection of hepatitis B virus in patients with orthotopic liver transplantation: analysis by determining complete sequence of the genome. J Med Virol. 2000;62:471–478
  6. Jilg W, Sieger E, Zachoval R, Schatzl H. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol. 1995;23:14–20
  7. Burton J, Shaw-Stiffel T. Use of hepatitis B core antibody positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States. Liver Transpl. 2003;9:837–842
  8. Perrillo R. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: a survey of North American, European, and Asian-Pacific transplant programs. Liver Transpl. 2009;15:223–232
  9. Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology. 1997;113:1668–1674
  10. Prieto M, Gomez MD, Berenguer M, Cordoba J, Rayon JM, Pastor M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl. 2001;7:51–58
  11. Manzarbeitia C, Reich DJ, Ortiz JA, Rothstein KD, Araya VR, Munoz SJ. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl. 2002;8:556–561
  12. Douglas D, Rakela J, Wright T, Krom RA, Wiesner RH. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg. 1997;3:105–111
  13. Shinji U, Kohachiro S, Hiroyuki M, Yukihiro I, Katsuhiro A, Hiroto E, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation. 1998;65:494–499
  14. Lee K, Wai C, Lim S, Manjit K, Lee HL, Da Costa M, et al. Risk for de novo hepatitis B from antibody to hepatitis B core antigen-positive donors in liver transplantation in Singapore. Liver Transpl. 2001;7:469
  15. Lo C, Fan S, Liu C, Yong BH, Wong Y, Ng IO, et al. Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. Liver Transpl. 2003;9:827–832
  16. Chen YS, Wang CC, deVilla VH, Wang SH, Cheng YF, Huang TL, et al. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transpl. 2002;16:405–409
  17. McQuillan G, Coleman P, Kruszon-Moran D, Moyer L, Lambert S, Margolis H. Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination Survey, 1976 through 1994. Am J Public Health. 1999;89:14–18
  18. Fontana RJ, Merion RM. Are we ready for marginal hepatitis B core antibody-positive living liver donors?. Liver Transpl. 2003;9:833–836
  19. Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E, et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl. 2001;7:513–517
  20. Joya-Vazquez FS, Dodson FS, Dvorchik I, Gray E, Chesky A, Demetris AJ, et al. Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation. 2002;73:1598–1602
  21. Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut. 2002;50:95–99
  22. Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, et al. Use of liver grafts from donors positive for anti-hepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation. 2003;75:1179–1186
  23. Montalti R, Nardo B, Bertelli R, Beltempo P, Puviani L, Vivarelli M, et al. Donor pool expansion in liver transplantation. Transplant Proc. 2002;36:520–522
  24. Donataccio D, Roggen F, De Reyck C, Verbaandert C, Bodeus M, Lerut J. Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool. Transpl Int. 2006;19:38–44
  25. Prakoso E, Strasser SI, Koorey DJ, Verran D, McCaughan GW. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transpl. 2006;20:369–373
  26. Celebi Kodak A, Karasu Z, Kilic M, Ozacar T, Tekin F, Gunsar F, et al. Living donor liver transplantation from hepatitis B core antibody positive donors. Transplant Proc. 2007;39:1488–1490
  27. De Feo T, Poli F, Mozzi F, Moretti MP, Scalamogna M Collaborative Kidney Liver and Heart North Italy Transplant Program Study Groups. Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study. Transplant Proc. 2005;37:1238–1239
  28. Suehiro T, Shimada M, Kishikawa K, Shimura T, Soejima Y, Yoshizumi T, et al. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. Liver Int. 2005;25:1169–1174
  29. Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation. 1997;64:1582–1584
  30. Crespo J, Fabrega E, Casafont F, Rivero M, Heras G, de la Pepa J, et al. Severe clinical course of de novo hepatitis B infection after liver transplantation. Liver Transpl Surg. 1999;5:175–183
  31. Holt CD, Thomas R, van Thiel DH, Brems JJ. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg. 2002;137:572–575
  32. Loss G, Mason A, Nair S, Blazek J, Farr G, Guo L, et al. Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors?. Liver Transpl. 2003;12:1258–1264
  33. Takemura N, Sugawara Y, Tamura S, Makuuchi M. Liver transplantation using hepatitis B core antibody-positive grafts: review and university of Tokyo experience. Dig Dis Sci. 2007;52:2472–2477
  34. Fabrega E, Garcia-Suarez C, Guerra A, Orive A, Casafont F, Crespo J, et al. Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. Liver Transpl. 2003;9:916–920
  35. Dodson F, Bonham C, Geller D, Cacciarelli TV, Rakela J, Fung JJ. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation. 1999;68:1058–1061
  36. Barcena R, Moraleda G, Moreno J, Dolore Martin M, de Vicente E, Nupo J, et al. Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers. World J Gastroenterol. 2006;12:2070–2074
  37. Barcena Marugan R, Garcia-Hoz F, Vazquez Romero M, Nash R, Mateos M, Gonzalez Alonso R, et al. Prevention of de novo hepatitis B infection in liver allograft recipients with previous hepatitis B infection or hepatitis B vaccination. Am J Gastroenterol. 2002;97:2398–2401
  38. Villamil I, Gonzalez-Quintela A, Aquilera A, Tome S, Otero E, Castroagudin FJ, et al. Truly de novo HBV infection after liver transplantation. Am J Gastroenterol. 2004;767–768
  39. Castells L, Vargas V, Rodrygez F, Allende H, Jardy R, Margarit C, et al. Transmission of hepatitis B virus by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Transplant Proc. 1999;31:2464–2465
  40. Nery JR, Gedaly R, Vianna R, Berho M, Weppler D, Levi DM, et al. Are liver grafts from hepatitis B surface antigen negative/anti-hepatitis B core antibody positive donors suitable for transplantation?. Transplant Proc. 2001;33:1521–1522
  41. Chazouilleres O, Mamish D, Kim M, Carey K, Ferrell L, Roberts J, et al. “Occult” hepatitis B virus as source of infection in liver transplant recipients. Lancet. 1994;343:142–146
  42. Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, et al. The risk of transmission of hepatitis B from HBsAg(−), HBcAb(+), HBIgM(−) organ donors. Transplantation. 1995;59:230–234
  43. Jain A, Orloff M, Abt P, Kashyap R, Mohanka R, Lansing K, et al. Use of hepatitis B core antibody positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and lamivudine. Transplant Proc. 2005;37:3187–3189
  44. Lin CC, Chen CL, Concejero A, Wang CC, Wang SH, Liu YW, et al. Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients. Am J Transplant. 2007;7:195–200
  45. Kwon C, Suh K, Yi N, Chang S, Cho Y, Lee H, et al. Long-term protection against hepatitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation. Pediatr Transplant. 2006;10:479–486
  46. Hwang S, Moon DB, Lee SG, Park KM, Kim KH, Ahn CS, et al. Safety of anti-hepatitis B core antibody-positive donors for living-donor liver transplantation. Transplantation. 2003;75:S45–S48
  47. Umeda M, Marusawa H, Ueda M, Takada Y, Egawa H, Uemoto S, et al. Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation. Am J Transplant. 2006;6:2680–2685
  48. Soejima Y, Ikegami T, Taketomi A, Yoshizumi T, Uchiyama H, Harada N, et al. Hepatitis B vaccination after living donor liver transplantation. Liver Int. 2007;27:977–982
  49. Park JB, Kwon CH, Lee KW, Choi GS, Kim DJ, Seo JM, et al. Hepatitis B virus vaccine switch program for prevention of de novo hepatitis B virus infection in pediatric patients. Transpl Int. 2008;21:346–352
  50. Lee K, Lee D, Lee H. Prevention of de novo hepatitis B infection from HbcAb-positive donors in living donor liver transplantation. Transplant Proc. 2004;36:2311–2312
  51. Papatheodoridis GV, Sevastianos V, Burroughs AK. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant. 2003;3:250–258
  52. Segovia R, Sanchez-Fueyo A, Rimola A, Grande L, Bruguera M, Costa J, et al. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation. Liver Transpl. 2001;7:106–112
  53. Gish RG, McCashland T. Hepatitis B in liver transplant recipients. Liver Transpl. 2006;12:S54–S64
  54. Sung J. Hepatitis B virus infection and its sequelae in Taiwan. Gastroenterol Jpn. 1984;19:363–366
  55. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology. 2000;32:1189–1195

PII: S0168-8278(09)00735-1

doi: 10.1016/j.jhep.2009.11.009

Journal of Hepatology
Volume 52, Issue 2 , Pages 272-279 , February 2010

Article Tools

* Image Usage & Resolution